



Antengene Plans to Adopt DeepSeek to Accelerate Drug Development on the AnTenGager™ Platform

Shanghai and Hong Kong, PRC, February 19, 2025 — Antengene Corporation Limited (**“Antengene”** , SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced **that the Company plans to expand its investment and consolidate resources to establish a dedicated artificial intelligence (“AI”) department. This initiative includes the on-site deployment of DeepSeek to accelerate the development of its next-generation proprietary T-cell engager (TCE) pipeline, which features a steric hindrance-masking technology.**

The Company has been strategically advancing AI-driven drug discovery since 2021, since it made an angel investment in MindRank AI’s drug discovery platform. This strategic move enabled the Company to harness AI capabilities internally, leading to the development of multiple small-molecule candidates. Through AI-based data modeling combined with multi-omics analysis, the Company also successfully identified a novel tumor-associated antigen (TAA) in hepatocellular carcinoma and advanced it to the preclinical validation stage as a TCE candidate –



positioning the Company as a pioneer in AI-powered drug discovery.

To strengthen its competitive edge, the Company plans to significantly increase its AI-focused R&D efforts. By integrating resources accumulated over the past four years and deploying DeepSeek locally, the Company will leverage targeted algorithms and AI-driven data mining to perform cross-database, multi-omics analyses. This approach enables effective ranking and selection of candidate proteins, thus identifying new tumor antigens suitable for TCE programs and accelerating the progression of the Company's TCE pipeline.

The Company's proprietary AnTenGager™ platform is a "2+1" TCE platform incorporating steric hindrance-masking technology, designed to enable disease-associated antigen (DAA)-dependent T-cell activation. This approach is intended to achieve potent therapeutic activity while reducing the risk of cytokine release syndrome (CRS). The bivalent binding to DAA enables detection and deep depletion of cells with low expression of the targets. Additionally, TCEs developed from the AnTenGager™ platform exhibit longer half-life, thereby reducing dosing frequency and enhancing clinical convenience.

The Company's lead TCE program, ATG-201, is a next-generation TCE



targeting CD19 x CD3 for B Cell-related autoimmune diseases, which has completed upstream chemical manufacturing and control (CMC) development and is expected to finalize investigational new drug (IND) preparation in Q3 2025. In addition to ATG-201, the Company's TCE pipeline also includes ATG-102, a LILRB4 x CD3 TCE for acute myeloid leukemia (AML) and chronic myelomonocytic leukemia; ATG-106, a CDH6 x CD3 TCE for ovarian cancer and kidney cancer; ATG-107, a FLT3 x CD3 TCE for AML; and ATG-110, a LY6G6D x CD3 TCE for microsatellite stable (MSS) colorectal cancer.

About Antengene

Antengene Corporation Limited ("**Antengene**" , SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "**Treating Patients Beyond Borders**".

Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and



Asia, and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand and Australia.

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2023, and the documents subsequently



submitted to the Hong Kong Stock Exchange.